U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™...
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab1 In RELATIVITY-047, Opdualagmore than...
news.bms.com